Mesoblast Ltd, of Melbourne, Australia, has drawn down a further $15 million from its $75 million four-year credit facility with Hercules Capital Inc. It said the funds will be used primarily to ramp up its commercialization programs, including building out a targeted sales force for remestemcel-L, an experimental therapy for acute graft-vs.-host disease for which Mesoblast plans to soon submit a rolling biologics license application to the FDA.